Article Text

Download PDFPDF
Case report
Acute reversible left ventricular systolic dysfunction associated with 5-fluorouracil therapy: a rare and increasingly recognised cardiotoxicity of a commonly used drug
  1. Tushar Mishra1,
  2. Mohamed Shokr2,
  3. Abdelrahman Ahmed3 and
  4. Luis Afonso2
  1. 1 Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA
  2. 2 Division of Cardiology, Wayne State University, Detroit, Michigan, USA
  3. 3 Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Dr Tushar Mishra, gm0583{at}wayne.edu

Abstract

5-Fluorouracil (5-FU) is the third most common chemotherapeutic agent for treating solid cancers and the second most common to cause cardiotoxicity. We present a rare case of acute reversible severe left ventricular systolic dysfunction associated with 5-FU. A 54-year-old woman with a history of stage IV gastric cancer presented with features of transient ischaemic attack after receiving the first dose of FLOT (5-FU, leucovorin, oxaliplatin and docetaxel). During the diagnostic workup, it was found that her ejection fraction was severely reduced to 15% with features of global hypokinesis, which later improved back to 65% within 13 days. These cases challenge our current understanding of the underlying mechanisms of this cardiotoxicity. Additionally, even though the patient did not experience any cardiac symptoms, it is important to monitor these patients closely as they are at high risk for fatal complications like arrhythmia and thrombus formation.

  • cardiovascular medicine
  • cancer - see oncology
  • heart failure
  • cancer intervention
  • cardiovascular system

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors Conceived of the presented idea and did the data collection: TM. Interpreted the data and drafted the article: TM and MS. Critically revised the article: MS, AA and LA. Final approval of the version to be published: TM, MS, AA and LA.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.